Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world selinexor in first-line high-risk multiple myeloma
ChiCTR2500096268Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-Free Survival. Started Jan 2025; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500096268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096268.